4-amino-5-hexynoic acid has been researched along with Huntington Disease in 1 studies
4-amino-5-hexynoic acid: structure
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "645), a potent irreversible inhibitor of gamma-aminobutyric acid transaminase, was given orally in various dosage schedules to 14 patients with Huntington disease." | 6.65 | Treatment of Huntington disease with gamma-acetylenic GABA an irreversible inhibitor of GABA-transaminase: increased CSF GABA and homocarnosine without clinical amelioration. ( Agid, Y; Böhlen, P; Bonnet, AM; Chazot, G; Coquillat, G; Fischer, C; Koch-Weser, J; Schechter, PJ; Tell, G, 1981) |
| "645), a potent irreversible inhibitor of gamma-aminobutyric acid transaminase, was given orally in various dosage schedules to 14 patients with Huntington disease." | 2.65 | Treatment of Huntington disease with gamma-acetylenic GABA an irreversible inhibitor of GABA-transaminase: increased CSF GABA and homocarnosine without clinical amelioration. ( Agid, Y; Böhlen, P; Bonnet, AM; Chazot, G; Coquillat, G; Fischer, C; Koch-Weser, J; Schechter, PJ; Tell, G, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tell, G | 1 |
| Böhlen, P | 1 |
| Schechter, PJ | 1 |
| Koch-Weser, J | 1 |
| Agid, Y | 1 |
| Bonnet, AM | 1 |
| Coquillat, G | 1 |
| Chazot, G | 1 |
| Fischer, C | 1 |
1 trial available for 4-amino-5-hexynoic acid and Huntington Disease
| Article | Year |
|---|---|
Treatment of Huntington disease with gamma-acetylenic GABA an irreversible inhibitor of GABA-transaminase: increased CSF GABA and homocarnosine without clinical amelioration.
Topics: 4-Aminobutyrate Transaminase; Adult; Aged; Alkynes; Aminocaproates; Brain; Brain Chemistry; Carnosin | 1981 |